Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL L LEONARDI

Allopathic & Osteopathic Physicians Pediatrics

NPI
1932295425
CMS profile
418556
Location
CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$888.89

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $875.00 1
Food and Beverage $13.89 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $875.00 1
Ironshore Pharmaceuticals Inc. $13.89 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL L LEONARDI

NPI 1932295425 · CMS profile ID 418556

Allopathic & Osteopathic Physicians / Pediatrics

CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932295425?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL L LEONARDI, NPI 1932295425, CMS profile ID 418556. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932295425?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MICHAEL L LEONARDI, NPI 1932295425, CMS profile ID 418556. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932295425?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MICHAEL L LEONARDI, NPI 1932295425, CMS profile ID 418556, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1932295425?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $888.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $875.0003/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753906641 CMS
Ironshore Pharmaceuticals Inc. $13.8902/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737042475 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25.81 3
PY2020 $888.89 2
PY2021 $18.05 1
PY2024 $53.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $55,396.18 17
PY2024 Principal investigator $110,737.73 24
PY2023 Principal investigator $174,788.60 91
PY2022 Principal investigator $755,230.68 69
PY2021 Principal investigator $485,798.70 79
PY2020 Principal investigator $231,870.31 96
PY2019 Principal investigator $225,139.83 126

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $307.69 12/31/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 826498487
Principal investigator 1 Merck Sharp & Dohme Corporation $46,413.06 12/31/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 848739629
Principal investigator 1 Merck Sharp & Dohme Corporation $304.68 12/31/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 848741155
Principal investigator 1 Merck Sharp & Dohme Corporation $15.86 12/31/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 848761773
Principal investigator 1 PFIZER INC. $1,582.52 12/23/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832553043
Principal investigator 1 SANOFI PASTEUR INC. $1,450.00 12/17/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376849
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 12/08/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS, PA
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 848739627
Principal investigator 1 PFIZER INC. $498.24 11/24/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832875329
Principal investigator 1 PFIZER INC. $548.35 11/24/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832899861
Principal investigator 1 ModernaTX, Inc. $113,484.40 11/17/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860944547
Principal investigator 1 SANOFI PASTEUR INC. $2,900.00 11/17/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376801
Principal investigator 1 SANOFI PASTEUR INC. $1,450.00 11/17/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376809
Principal investigator 1 PFIZER INC. $632.99 11/05/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832836207
Principal investigator 1 SANOFI PASTEUR INC. $800.00 10/27/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376787
Principal investigator 1 PFIZER INC. $864.90 10/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832869445
Principal investigator 1 PFIZER INC. $249.12 10/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832884703
Principal investigator 1 GlaxoSmithKline, LLC. $1,304.10 10/13/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS
Not supplied No dispute reported 06/30/2026 809527539
Principal investigator 1 PFIZER INC. $632.99 10/08/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832785221
Principal investigator 1 PFIZER INC. $249.12 10/08/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832803321
Principal investigator 1 ModernaTX, Inc. $146,927.07 10/06/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS PA
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860944549
Principal investigator 1 PFIZER INC. $1,497.89 09/22/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832840139
Principal investigator 1 PFIZER INC. $1,729.80 09/04/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832812445
Principal investigator 1 PFIZER INC. $747.36 09/04/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832890003
Principal investigator 1 PFIZER INC. $3,736.80 08/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832733445
Principal investigator 1 PFIZER INC. $1,413.25 08/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832801203
Principal investigator 1 SANOFI PASTEUR INC. $2,600.00 08/20/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376757
Principal investigator 1 PFIZER INC. $1,683.84 08/07/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832873481
Principal investigator 1 PFIZER INC. $1,497.89 08/06/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832801193
Principal investigator 1 PFIZER INC. $3,628.77 07/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832720705
Principal investigator 1 PFIZER INC. $802.49 07/20/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832526431
Principal investigator 1 PFIZER INC. $1,417.20 07/20/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832526563
Principal investigator 1 SANOFI PASTEUR INC. $3,600.00 07/19/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376741
Principal investigator 1 PFIZER INC. $864.90 07/09/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832712581
Principal investigator 1 PFIZER INC. $4,007.95 06/29/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832916513
Principal investigator 1 SANOFI PASTEUR INC. $1,800.00 06/25/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376709
Principal investigator 1 PFIZER INC. $687.36 06/23/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832828319
Principal investigator 1 PFIZER INC. $1,729.80 06/09/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832823301
Principal investigator 1 PFIZER INC. $687.36 06/05/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832879835
Principal investigator 1 SANOFI PASTEUR INC. $1,950.00 06/04/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376721
Principal investigator 1 GlaxoSmithKline, LLC. $1,028.70 06/01/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS
Not supplied No dispute reported 06/30/2026 809518981
Principal investigator 1 PFIZER INC. $776.70 05/24/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832924049
Principal investigator 1 PFIZER INC. $5,075.03 05/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832704119
Principal investigator 1 PFIZER INC. $2,284.74 05/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832846919
Principal investigator 1 PFIZER INC. $258.90 05/11/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832696833
Principal investigator 1 PFIZER INC. $75.74 05/11/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832795103
Principal investigator 1 PFIZER INC. $8,450.00 05/08/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832643821
Principal investigator 1 PFIZER INC. $4,691.16 05/07/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832718143
Principal investigator 1 PFIZER INC. $3,194.76 05/07/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832743799
Principal investigator 1 SANOFI PASTEUR INC. $2,250.00 04/28/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376683
Principal investigator 1 PFIZER INC. $54.10 04/26/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832707487
Principal investigator 1 PFIZER INC. $431.50 04/26/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832920283
Principal investigator 1 PFIZER INC. $3,210.48 04/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832736015
Principal investigator 1 PFIZER INC. $2,749.44 04/21/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832847235
Principal investigator 1 PFIZER INC. $54.10 04/16/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832919713
Principal investigator 1 PFIZER INC. $86.30 04/16/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832923061
Principal investigator 1 PFIZER INC. $11,907.78 04/09/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832713353
Principal investigator 1 PFIZER INC. $3,210.48 04/09/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832811821
Principal investigator 1 PFIZER INC. $517.80 04/05/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832781281
Principal investigator 1 PFIZER INC. $64.92 04/05/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832812435
Principal investigator 1 GlaxoSmithKline, LLC. $1,107.00 03/24/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS
Not supplied No dispute reported 06/30/2026 809486355
Principal investigator 1 PFIZER INC. $5,708.02 03/24/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832717835
Principal investigator 1 PFIZER INC. $5,256.84 03/24/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832891763
Principal investigator 1 PFIZER INC. $258.90 03/15/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832823311
Principal investigator 1 PFIZER INC. $32.46 03/15/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832836263
Principal investigator 1 PFIZER INC. $3,882.12 03/05/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832843593
Principal investigator 1 SANOFI PASTEUR INC. $1,300.00 03/05/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376657
Principal investigator 1 PFIZER INC. $54.10 02/24/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832696767
Principal investigator 1 PFIZER INC. $6,420.96 02/24/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832784873
Principal investigator 1 PFIZER INC. $431.50 02/24/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832911541
Principal investigator 1 PFIZER INC. $32,320.32 02/23/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832706767
Principal investigator 1 PFIZER INC. $5,250.00 02/12/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 SINGLEARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 832890011
Principal investigator 1 GlaxoSmithKline, LLC. $1,107.00 02/10/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS
Not supplied No dispute reported 06/30/2026 809486915
Principal investigator 1 GlaxoSmithKline, LLC. $1,272.60 01/20/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS
Not supplied No dispute reported 06/30/2026 809486313
Principal investigator 1 SANOFI PASTEUR INC. $800.00 01/19/2021 Non-covered Recipient Entity
Palmetto Pediatrics,PA
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838376625
Principal investigator 1 PFIZER INC. $864.90 01/16/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832906563
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,368.40 01/15/2021 Non-covered Recipient Entity
PALMETTO PEDIATRICS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 826494713
Principal investigator 1 PFIZER INC. $517.80 01/12/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832875339
Principal investigator 1 PFIZER INC. $64.92 01/12/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832924059
Principal investigator 1 PFIZER INC. $3,210.48 01/09/2021 Non-covered Recipient Entity
Palmetto Pediatrics PA
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832776187